· .. and atenolol in mild to moderate hypertension

The antihypertensive efficacy of lacidipine [GR 43659, GR 43659X, GX 1048, SN 305; Glaxo, Mochida, Zambon, Boehringer Ingelheim] was shown to equal that of atenolol in a 5-month, double-blind comparative study of patients with mild to moderate hypertension followed by a 9-month open phase.

268 patients received lacidipine 4 mg/day, increased to 6 mg/day after 4 weeks in 152, with hydrochlorothiazide added to the regimen of 76 patients after a further 4 weeks. 265 patients received atenolol 50 mg/day increased to 100 ~n/~",,, ;"" 110 _.,t;o't"d~ "'; ... "" \.,,,.rl .............. hl,, ..... ··d·""';., ....... ;,...1,, I"'bl''''''"'') 11.1 a, ,,1 l-',",U\,..J..llJ nU,l.lllJU1V\,..J.I.lU1VLllU1LlU\....

added in 50 patients. Adverse effects were reported in 56.3% of lacidipine and 50.2% of atenolol recipients (NS). Flushing, headache and oedema were common with lacidipine, while malaise, fatigue, headache and oedema were common with atenolol. One dcath from myocardial infarction was considered to possibly be related to lacidipine therapy. United Kingdom Lacidipine Study Group. A double-blind comparison of the efficacy and safety of lacidipine with atenolol in the treatment of essential hypertension. Journal of Cardiovascular Pharmacology 17 (Suppl 4): 27-29. 1991 ""

ISSN 0156-2703/91/0706-0005/0$01.00/0 © Adis International Ltd 5

INPHARMA®6 lui 1991